Skip to: Curated Story Group 1
Visually Open Nav.
Advertise
with us
US
EUROPE
APAC
CANADA
LATAM
subscribe
Open Search Field.
Home
Topics
Biomanufacturing
Biomanufacturing
Biomanufacturing
Biomanufacturing
Biomanufacturing
Business Services
Business Services
Business Services
Business Services
Business Services
Drug Discovery
Drug Discovery
Drug Discovery
Drug Discovery
Drug Discovery
Pharmacy Management
Regulatory Services
CXO Insights
Vendor Viewpoint
News
Conferences
Newsletter
Whitepapers
Magazine
CXO Awards
NOVEMBER 2023LIFE SCIENCES REVIEW6The life sciences consulting market in Europe is subject to many influential factors that affect the demand for consulting services. According to a recent article by the European Pharmaceutical Review, the life sciences industry in Europe is expected to face significant regulatory changes in 2023. These changes span five key areas, including clinical trials, medical devices, pharmaceutical legislation, class actions, and the regulation of artificial intelligence (AI). In addition, the potential introduction of class action mechanisms and AI regulation initiatives highlights the changing landscape in the European life sciences sector.One of the most important factors is the regulatory environment that governs the life sciences industry, with changes in regulations related to drug approvals, clinical trials, and data privacy necessitating consulting support for navigating complex compliance frameworks. Economic factors such as GDP growth, inflation rates, and government healthcare spending significantly impact businesses' willingness to invest in consulting services. This edition of Life Sciences Review features life sciences consulting services providers in Europe that have emerged as the forerunners in the industry despite the market challenges and roadblocks. It covers Fuliginous Management Consulting, a management consulting firm that provides consulting services to the pharmaceutical contract manufacturing industry. The firm offers services to both CDMOs and pharmaceutical companies cooperating with CDMOs. The company's objective is to help clients identify the issues hindering their progress and design appropriate strategies in the future, requiring deep and integrated market knowledge and an unbiased and objective view.It also includes the valuable perspectives of Dr Linda Randall, AVP, Biologics Development, Manufacturing & Control at Pharmaron [SHE: 300759], and Xavier Salas, Corporate Legal & Compliance Manager at Neuraxpharm. They share their views on the current state of the life sciences consulting industry in Europe, its challenges, and its prospects.Let us know your thoughts!EDITORIALFactors Influencing the Life Sciences Consulting Market in EuropeCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsNovember - 30 - 2023, Vol 04, Issue - 39 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
<
Page 5
|
Page 7
>